Evidence mapPaperPMID 36141012Full record

ReviewFoods (Basel, Switzerland)2022

Are Nutraceuticals Effective in COVID-19 and Post-COVID Prevention and Treatment?

Alessia Catalano, Domenico Iacopetta, Jessica Ceramella, Azzurra Chiara De Maio, Giovanna Basile, Federica Giuzio, Maria Grazia Bonomo, Stefano Aquaro, Thomas J Walsh, Maria Stefania Sinicropi and 3 more

Open access · goldAbstract readReview
In one paragraph

Review in Foods (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 42 citations in OpenAlex.

  1. Molecules (Basel, Switzerland) · 2026
    Review
  2. Observational
  3. Review
  4. Article
  5. COVID-19-Where Are We Now.Current medicinal chemistry · 2025
    Article
  6. Article
  7. Article
  8. Review
  9. Foods (Basel, Switzerland) · 2024
    Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Diarylureas: New Promising Small Molecules againstAntibiotics (Basel, Switzerland) · 2023
    Review
  19. Article
  20. Drugs for COVID-19: An Update.Molecules (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Alessia CatalanoDepartment of Pharmacy-Drug Sciences, University of Bari "Aldo Moro", 70126 Bari, Italy.ORCID 0000-0002-7420-4706
Domenico IacopettaDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Arcavacata di Rende, Italy.ORCID 0000-0001-5179-7118
Jessica CeramellaDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Arcavacata di Rende, Italy.ORCID 0000-0002-1386-3601
Azzurra Chiara De MaioDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Arcavacata di Rende, Italy.
Giovanna BasileDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Arcavacata di Rende, Italy.
Federica GiuzioDepartment of Science, University of Basilicata, 85100 Potenza, Italy.
Maria Grazia BonomoDepartment of Science, University of Basilicata, 85100 Potenza, Italy.ORCID 0000-0001-6675-4276
Stefano AquaroDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Arcavacata di Rende, Italy.ORCID 0000-0002-8417-2103
Thomas J WalshCenter for Innovative Therapeutics and Diagnostics, Richmond, VA 23223, USA.
Maria Stefania SinicropiDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Arcavacata di Rende, Italy.ORCID 0000-0003-2435-8931
Carmela SaturninoDepartment of Science, University of Basilicata, 85100 Potenza, Italy.ORCID 0000-0002-7419-8780
Athina GeronikakiSchool of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.ORCID 0000-0001-9894-7777
Giovanni SalzanoDepartment of Science, University of Basilicata, 85100 Potenza, Italy.
University of Calabria · ITUniversity of Basilicata · ITAristotle University of Thessaloniki · GRInnovative Clinical Research · USUniversity of Bari Aldo Moro · IT

Funding

Ministry of Education, Universities and Research 1062_R13_GREEN
6 · The paper itself

Abstract

The beginning of the end or the end of the beginning? After two years mastered by coronavirus disease 19 (COVID-19) pandemic, we are now witnessing a turnaround. The reduction of severe cases and deaths from COVID-19 led to increasing importance of a new disease called post-COVID syndrome. The term post-COVID is used to indicate permanency of symptoms in patients who have recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Immune, antiviral, antimicrobial therapies, as well as ozone therapy have been used to treat COVID-19 disease. Vaccines have then become available and administered worldwide to prevent the insurgence of the disease. However, the pandemic is not over yet at all given the emergence of new omicron variants. New therapeutic strategies are urgently needed. In this view, great interest was found in nutraceutical products, including vitamins (C, D, and E), minerals (zinc), melatonin, probiotics, flavonoids (quercetin), and curcumin. This review summarizes the role of nutraceuticals in the prevention and/or treatment of COVID-19 disease and post-COVID syndrome.

Indexed as

flavonoidslong-COVIDnatural bioactive compoundsquercetinSARS-CoV-2vitaminszinc

Identifiers

PMID36141012
PMCPMC9498392
OpenAlexW4296307209

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.